obesity drug news today glp-1 september 29 2025 New oral drugs could offer more options for weight loss The GLP-1 Access Gap: Mapping
Description
Caroline Fontana
Consistent with this concept, up to 30% of individuals with PsO eventually develop PsA, a chronic inflammatory arthropathy affecting peripheral joints, entheses, and the axial skeleton (10)
Here are the details
Studies have shown that sitagliptin is a selective and potent inhibitor (greater than 80%) of the DPP-4 enzyme
[cited 2023 Nov 18]
[(accessed on 15 November 2021)]
